Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression

Area of Science:

• Neurology
• Nutritional Science
• Epidemiology

Background:

• Multiple sclerosis (MS) is a chronic neurological disease.
• Dietary intake of alpha-linolenic acid (ALA), an omega-3 fatty acid, may influence MS risk and progression.
• Previous studies suggest a protective role for ALA in MS.

Purpose of the Study:

• To investigate the association between serum levels of ALA and other polyunsaturated fatty acids (PUFAs) and MS outcomes.
• To predict MS disease activity and progression based on fatty acid profiles.
• To examine these associations over an 11-year period post-clinical onset.

Main Methods:

• Prospective cohort study within the BENEFIT clinical trial.
• Serum fatty acid analysis using gas chromatography.
• Cox, negative binomial, and linear regression models to assess associations with MS outcomes.

Main Results:

• Higher baseline serum ALA levels were associated with a significantly lower risk of clinically definite MS (CDMS) and relapses at both 5 and 11 years.
• ALA levels correlated with a slower decline in the MS Functional Composite score, indicating less disability progression.
• No significant associations were found for other fatty acids with CDMS risk or long-term progression.

Conclusions:

• Elevated serum ALA levels are associated with reduced risk of MS diagnosis and relapses.
• ALA may play a protective role in multiple sclerosis progression and disability.
• Serum fatty acid profiles, particularly ALA, could serve as biomarkers for MS risk and prognosis.